AbbVie plans to acquire Gilgamesh Pharmaceuticals for $1 billion to accelerate the transformation of the era of Humira.

According to informed sources, biopharmaceutical giant AbbVie is in advanced negotiations to acquire Gilgamesh Pharmaceuticals for approximately $1 billion. If the deal is reached, it will mark another strategic move by the pharmaceutical company to expand its pipeline after the patent of its blockbuster drug Humira expires. Data shows that AbbVie has already invested over $20 billion in merger and acquisition transactions since 2023.